Pharmaceutical News

Merck KGaA Lupus Drug Trial Update: Enpatoran Phase 2 Insights Merck Autoimmune Merck KGaA reveals detailed results from its phase 2 lupus trial of enpatoran, highlighting mixed outcomes in different patient cohorts and plans to pursue regulatory approval based on promising secondary endpoint data.
Nuvation Bio's Ibtrozi Gains FDA Nod to Compete in Lung Cancer Market FDA Nuvation Bio Cancer Nuvation Bio’s Ibtrozi (taletrectinib) secures FDA approval for treating ROS1-positive non-small cell lung cancer, offering a next-gen alternative to Pfizer, BMS, and Roche therapies with strong efficacy and CNS safety.
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal BMS Biotech Philochem Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
Elevation Oncology Acquired After Ending Partnership with CSPC CSPC Elevation Oncology Elevation Oncology has been acquired by Concentra Biosciences after halting its Claudin18.2 ADC program with CSPC. The deal includes a $22M valuation and future rights tied to EO-1022, its sole remaining HER3-targeted ADC candidate.
Klotho Neurosciences Extends Lifespan by 20%, Stock Soars 788% w Klotho Neurosciences Biotech Anti-aging Klotho Neurosciences announces a breakthrough in anti-aging research, extending lifespan by 20% in mice using AAV-Klotho gene therapy. Stock price surges 788% on the news.
Pfizer's Strategic Bet on Bispecifics Pfizer Akeso Pfizer commits up to $6B for rights to SSGJ-707, a PD-1xVEGF bispecific, after in-depth due diligence in China. The asset is expected to complement Pfizer’s ADC portfolio and advance its oncology strategy.
FDA Puts Gilead’s HIV Combo Trials on Hold Gilead HIV FDA The FDA has paused five Gilead HIV combo trials over safety concerns, but the decision does not impact lenacapavir's upcoming PrEP approval. Gilead remains confident in its HIV pipeline and future plans.
FDA Narrows Use of PD-1 Drugs in GI Cancers FDA PD-1 The FDA has restricted Merck’s Keytruda and BMS’s Opdivo for use only in PD-L1-positive gastric, GEJ, and esophageal cancers, citing limited benefit in PD-L1-negative patients based on recent trial data.
George Medicines Gains FDA Nod for Hypertension Triple-Combo Pill FDA George Medicines George Medicines'Widaplik, a first-of-its-kind triple-combination pill for hypertension, gains FDA approval for initial treatment. U.S. launch planned in Q4 2025.
Merck Advances Oral PCSK9 Inhibitor with Phase 3 Success Merck Merck achieves successful phase 3 trial results for enlicitide, an oral PCSK9 inhibitor, showing significant cholesterol reduction and a strong safety profile, advancing toward potential 2027 approval.